By targeting both survival and metastatic programs, olivomycin A may offer a therapeutic advantage over agents that act on a single pathway, particularly in tumors harboring p53, VHL, and PTEN mutations, which constitute a subset of aggressive RCC subtypes [27,28,29,30]. This evidence concerns the gene TP53 and renal cell adenocarcinoma.